PropertyValue
?:abstract
  • Coronavirus disease 2019 (COVID-19), the highly contagious illness caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread across the globe, becoming one of the most challenging public health crisis of our times SARS-CoV-2 can cause severe disease associated with multiple organ damage Cancer patients have a higher risk of SARS-CoV-2 infection and death While the virus uses angiotensin-converting enzyme 2 (ACE2) as the primary entry receptor, the recent experimental and clinical findings suggest that some tumor markers, including CD147 (basigin), can provide an additional entry for SARS-CoV-2 infection through binding to the viral spike (S) protein In the absence of specific viral drugs, blocking of CD147 might be a way to prevent virus invasion Identifying other target proteins is of high importance as targeting the alternative receptors for SARS-CoV-2 might open up a promising avenue for the treatment of COVID-19 patients, including those who have cancer
is ?:annotates of
?:creator
?:journal
  • FEBS_Journal
?:license
  • unk
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:source
  • WHO
?:title
  • Tumor markers as an entry for SARS-CoV-2 infection? (Special Issue: COVID-19.)
?:type
?:who_covidence_id
  • #960856
?:year
  • 2020

Metadata

Anon_0  
expand all